Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer

Cancer Research

Volumn 63, Issue 5, 2003, Pages 1101-1105

  Kang, Jung Y ^a   Dolled Filhart, Marisa ^a   Ocal, Idris Tolgay ^a   Singh, Baljit ^b   Lin, Chen Yong ^b   Dickson, Robert B ^b   Rimm, David L ^a   Camp, Robert L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 1; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DNA MICROARRAY; FOLLOW UP; GENE ACTIVATION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

BREAST NEOPLASMS; HEPATOCYTE GROWTH FACTOR; HUMANS; MEMBRANE GLYCOPROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTORS, GROWTH FACTOR; SERINE ENDOPEPTIDASES; TRANS-ACTIVATORS; TRYPSIN;

EID: 0037374303     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Danilkovitch-Miagkova, A., and Zbar, B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J. Clin. Investig., 109: 863-867, 2002.
2. Yao, Y., Jin, L., Fuchs, A., Joseph, A., Hastings, H. M., Goldberg, I. D., and Rosen, E. M. Scatter factor protein levels in human breast cancers: clinicopathological and biological correlations. Am. J. Pathol., 149: 1707-1717, 1996.
3. Jin, L., Fuchs, A., Schnitt, S. J., Yao, Y., Joseph, A., Lamszus, K., Park, M., Goldberg, I. D., and Rosen, E. M. Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer (Phila.), 79: 749-760, 1997.
4. Tsao, M. S., Yang, Y., Marcus, A., Liu, N., and Mou, L. Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer. Hum. Pathol., 32: 57-65, 2001.
5. Wang, Y., Selden, A. C., Morgan, N., Stamp, G. W., and Hodgson, H. J. Hepatocyte growth factor/scatter factor expression in human mammary epithelium. Am. J. Pathol., 144: 675-682, 1994.
6. Lee, S. L., Dickson, R. B., and Lin, C. Y. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J. Biol. Chem., 275: 36720-36725, 2000.
7. Tanimoto, H., Underwood, L. J., Wang, Y., Shigemasa, K., Parmley, T. H., and O'Brien, T. J. Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention. Tumor Biol., 22: 104-114, 2001.
8. Oberst, M., Anders, J., Xie, B., Singh, B., Ossandon, M., Johnson, M., Dickson, R. B., and Lin, C. Y. Matriptase and HAI-I are expressed by normal and malignant epithelial cells in vitro and in vivo. Am. J. Pathol., 158: 1301-1311, 2001.
9. Lin, C. Y., Anders, J., Johnson, M., and Dickson, R. B. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J. Biol. Chem., 274: 18237-18242, 1999.
10. Shimomura, T., Denda, K., Kitamura, A., Kawaguchi, T., Kito, M., Kondo, J., Kagaya, S., Qin, L., Takata, H., Miyazawa, K., and Kitamum, N. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J. Biol. Chem., 272: 6370-6376, 1997.
11. Boccaccio C., Ando, M., Tamagnone, L., Bardelli, A., Michieli, P., Battistini, C., and Comoglio, P. M. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature (Lond.), 391: 285-288, 1998.
12. Edakuni, G., Sasatomi, E., Satoh, T., Tokunaga, O., and Miyazaki, K. Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol. Int., 51: 172-178, 2001.
13. Oberst, M. D., Johnson, M. D., Dickson, R. B., Lin, C. Y., Singh, B., Stewart, M., Williams, A., al-Nafussi, A., Smyth, J. F., Gabra, H., and Sellar, G. C. Expression of the serine protease matriptase and its inhibitor HAI-I in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin. Cancer Res., 8: 1101-1107, 2002.
14. Ihara, S., Miyoshi, E., Ko, J. H., Murata, K., Nakahara, S., Honke, K., Dickson, R. B., Lin, C. Y., and Taniguchi, N. Prometastatic effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding β 1-6 GlcNAc branching. J. Biol. Chem., 277: 16960-16967, 2002.
15. Park, W. S., Dong, S. M., Kim, S. Y., Na, E. Y., Shin, M. S., Pi, J. H., Kim, B. J., Bae, J. H., Hong, Y. K., Lee, K. S., Lee, S. H., Yoo, N. J., Jang, J. J., Pack, S., Zhuang, Z., Schmidt, L., Zbar, B., and Lee, J. Y. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res., 59: 307-310, 1999.
16. Di Renzo, M. F., Olivero, M., Martone, T., Maffe, A., Maggiora, P., Stefani, A. D., Valente, G., Giordano, S., Cortesina, G., and Comoglio, P. M. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene, 19: 1547-1555, 2000.
17. Moon, Y. W., Weil, R. J., Pack, S. D., Park, W. S., Pak, E., Pham, T., Karkera, J. D., Kim, H. K., Vortmeyer, A. O., Fuller, B. G., and Zhuang, Z. Missense mutation of the MET gene detected in human glioma. Mod. Pathol., 13: 973-977, 2000.
18. Schmidt, L., Duh, F. M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., Allikmets, R., Chidambaram, A., Bergerheim, U. R., Feltis, J. T., Casadevall, C., Zamarron, A., Bernues, M., Richard, S., Lips, C. J., Walther, M. M., Tsui, L. C., Geil, L., Orcutt, M. L., Stackhouse, T., Zbar, B., and et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet., 16: 68-73, 1997.
19. Lee, J. H., Han, S. U., Cho, H., Jennings, B., Gerrard, B., Dean, M., Schmidt, L., Zbar, B., and Vande Woude, G. F. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene, 19: 4947-4953, 2000.
20. Cooper, C. S., Park, M., Blair, D. G., Tainsky, M. A., Huebner, K., Croce, C. M., and Vande Woude, G. F. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature (Lond.), 311: 29-33, 1984.
21. Rodrigues, G. A., and Park, M. Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase. Mol. Cell. Biol., 13: 6711-6722, 1993.
22. Zhen, Z., Giordano, S., Longati, P., Medico, E., Campiglio, M., and Comoglio, P. M. Structural and functional domains critical for constitutive activation of the HGF-receptor (Met). Oncogene, 9: 1691-1697, 1994.
23. Wallenius, V., Hisaoka, M., Helou, K., Levan, G., Mandahl, N., Meis-Kindblom, J. M., Kindblom, L. G., and Jansson, J. O. Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors. Am. J. Pathol., 156: 821-829, 2000.
24. Rusciano, D., Lorenzoni, P., and Burger, M. M. Constitutive activation of c-Met in liver metastatic B16 melanoma cells depends on both substrate adhesion and cell density and is regulated by a cytosolic tyrosine phosphatase activity. J. Biol. Chem., 271: 20763-20769, 1996.
25. Rimm, D. L., Camp, R. L., Charette, L. A., Olsen, D. A., and Provost, E. Amplification of tissue by construction of tissue microarrays. Exp. Mol. Pathol., 70: 255-264, 2001.
26. Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., and Kallioniemi, O. P. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med., 4: 844-847, 1998.
27. Camp, R. L., Charette, L. A., and Rimm, D. L. Validation of tissue microarray technology in breast carcinoma. Lab. Investig., 80: 1943-1949, 2000.
28. Torhorst, J., Bucher, C., Kononen, J., Haas, P., Zuber, M., Kochli, O. R., Mross, F., Dieterich, H., Moch, H., Mihatsch, M., Kallioniemi, O. P., and Sauter, G. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am. J. Pathol., 159: 2249-2256, 2001.
29. Norton, A. J., Jordan, S., and Yeomans, P. Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J. Pathol., 173: 371-379, 1994.
30. Lin, C. Y., Wang, J. K., Torri, J., Dou, L., Sang, Q. A., and Dickson, R. B. Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. Monoclonal antibody production, isolation, and localization. J. Biol. Chem., 272: 9147-9152, 1997.
31. Oberst, M., Lin, C. Y., Dickson, R. B., and Johnson, M. Role of Proteases in Breast Cancer. J. Women Cancer, 2: 201-216, 2002.
32. Look, M. P., van Putten, W. L., Duffy, M. J., Harbeck, N., Christensen, I. J., Thomssen, C., Kates, R., Spyratos, F., Ferno, M., Eppenberger-Castori, S., Sweep, C. G., Ulm, K., Peyrat, J. P., Martin, P. M., Magdelenat, H., Brunner, N., Duggan, C., Lisboa, B. W., Bendahl, P. O., Quillien, V., Daver, A., Ricolleau, G., Meijer-van Gelder, M. E., Manders, P., Fiets, W. E., Blankenstein, M. A., Broet, P., Romain, S., Daxenbichler, G., Windbichler, G., Cufer, T., Borstnar, S., Kueng, W., Beex, L. V., Klijn, J. G., O'Higgins, N., Eppenberger, U., Janicke, F., Schmitt, M., and Foekens, J. A. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl. Cancer Inst., 94: 116-128, 2002.
33. Andreasen, P. A., Kjoller, L., Christensen, L., and Duffy, M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer, 72: 1-22, 1997.
34. Takeuchi, T., Harris, J. L., Huang, W., Yan, K. W., Coughlin, S. R., and Craik, C. S. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J. Biol. Chem., 275: 26333-26342, 2000.
35. Mars, W. M., Zarnegar, R., and Michalopoulos, G. K. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am. J. Pathol., 143: 949-958, 1993.
36. Kataoka, H., Hamasuna, R., Itoh, H., Kitamura, N., and Koono, M. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma. Cancer Res., 60: 6148-6159, 2000.
37. Bajou, K., Noel, A., Gerard, R. D., Masson, V., Brunner, N., Holst-Hansen, C., Skobe, M., Fusenig, N. E., Carmeliet, P., Collen, D., and Foidart, J. M. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med., 4: 923-928, 1998.